

Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa)

Date: 04/01/2023

Ref. No. CDT/030/23

To: World Bank-Financial Management Team


Ethiopia Country Office
Addis Ababa

Subject: **Submission of CDT-Africa annual audit report for the year ended July 07, 2022**

Attached here please find the audit reports for the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University. The report consists of;

1) Independent Auditors' Reports, 2) The statements of Financial Position, 3) The statement of sources and use of funds, 4) Statement of Reimbursable Eligible Expenditure Programs (EEPs), 5) The statement of Designated Account-IDA, 6) Notes to the Financial Statements, and 7) List of Fixed Asset Acquisition for the year ended July 07, 2022.

With kind regards,



Professor Abebaw Fekadu, MD, PhD
Head, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa)
College of Health Sciences
Addis Ababa University

CC:

- Budget and Finance Directorate- Addis Ababa University (AAU)
- Chief Executive Director (CHS)
- Finance Office, CDT-Africa Finance, (CHS)
Addis Ababa



Chartered Certified Accountants and Authorized Auditors
የተመሰከረላቸው የሂሳብ አዋቂዎችና የተፈቀደላቸው አዲተሮች

HST General Partnership
Ethio-China Avenue; Wollo Sefer
Mina Building 5th Floor
P.O. Box 1608
Addis Ababa
Ethiopia

Tel.: +251 115 527666/67
Fax.: +251 115 528384
Email: info@hst.et.com
www.hst-et.com

Ref. No.: HST/03822/A/2023
Date: 05 January 2023

Addis Ababa University Center for Innovative Drug Development and
Therapeutic Trials for Africa (CDT-Africa)

Dear Sir,

Subject; Submission of Final Auditors' Report

We are pleased to submit six copies of the Reports and Financial Statements of Addis Ababa University Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa) for the Period ended 07 July 2022.

Yours faithfully,

Thomas Mulugeta
Partner

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC
TRIALS FOR AFRICA (CDT- AFRICA)
REPORT AND FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 07 JULY 2022

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

GLOSSARY OF TERMS

ETB	Ethiopian Birr
CDT	Center for Innovative Drug Development and Therapeutic Trials

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

TABLE OF CONTENTS	Pages
PART 1 INTRODUCTION	
1.1 Background	4
1.2 Project description	4
1.3 Audit objectives	4
1.4 Audit scope	4
1.5 Audit methodology	5
1.6 Results of the audit	6
PART 2 STATEMENT OF MANAGEMENT'S RESPONSIBILITIES	7
PART 3 INDEPENDENT AUDITORS' REPORT ON THE SPECIAL PURPOSE FINANCIAL STATEMENTS	
3.1 Independent auditors' report	8-9
Statement of Financial Position	10
Statement of Changes In Fund Balances	12
3.2 Statement of Income and Expenditure	13
3.3 Notes to the special purpose financial statements	14-17
PART 4 INDEPENDENT AUDITORS' REPORT ON COMPLIANCE	18
PART 5 INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL	19
Annex 1 Uses of Funds by Project Component and category of 7 July 2022	20-24
Annex 2 Fixed Asset Listing as of 7 July 2022	25-27

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

1 INTRODUCTION

1.1 Background

The Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa) is an Africa Centre of Excellence established, through a highly competitive award of the World Bank, to help improve access to essential medicines for millions in Africa. The center is one of the three centers of excellence under the Addis Ababa University. It runs several education and research programs.

CDT-Africa partners with a large number of national and regional institutions, including leading international institutions, such as King's College London, University of Sussex, Brighton and Sussex Medical School and the Harvard, as key knowledge partners.

1.2 Project description

The core task of CDT-Africa is to increase human and infrastructure capacity through high quality trainings, research and by strengthening the management of education and research. Training and research programs support therapeutic discovery through the following activities: (1) establishment of a database of scientifically tested natural products, which serves as resource for translational research and accelerate pharmaceutical innovation in Eastern and Southern Africa; (2) Conduct drug discovery studies using database; (3) Repurpose currently available interventions, formulation and reformulation; (4) Bioequivalence and pharmacogenetic studies of medicines to ensure safety and effectiveness; (5) Implementation of pharmaco-economic evaluations; (6) Build foundational skills and assets to innovative point-of-care diagnostics; (7) Support skill development for industrial manufacturing in the region; (8) Establish sustainable impact through medicinal plants conservation, public and policy engagement and sustainable financing. The total amount of fund granted from the World Bank is \$6,000,000 although the actual value of the project is much higher.

1.3 Audit objectives

The objective of the audit is to express an opinion on CDT-Africa financial statements for the CDT-Africa for the period from July 8, 2021- July 7, 2022. The audit includes but not limited to the following tasks:

- Perform reviews of the accounting records and ascertain whether the laid down financial procedures are complied with;
- Review and evaluate the Project's accounting policies and administrative controls and report any significant weaknesses, together with recommendations for improvement and ensure that the respective accounts manual is updated in accordance with the respective guidelines;
- Determine whether the management and financial systems, including internal controls, within the components are adequate for efficient and prudent management of funds;
- Review the use of funds vis a vis approved budgets in relation to the agreement between International Development Association (IDA) and carried out by the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa) and the Federal Democratic Republic of Ethiopia (FDRE).
- Recommend possible improvements and/or actions in any area on financial management and especially areas where weaknesses were noted; and
- Follow up on the status of prior period audit recommendations, if any.

1.4 Audit scope

The audit scope required us to carry out sufficient audit steps and procedures to ensure that the audit objectives were met for the period from July 8, 2021- July 7, 2022. Details of the steps and procedures are given below.

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

1 INTRODUCTION (continued)

1.5 Audit Methodology

We conducted the audit in accordance with International Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the statement of income and expenditure and financial position of the project is free from material misstatement.

Internal controls

Evaluated internal controls to obtain a sufficient understanding of the design of relevant controls, policies and procedures and whether they have been in operation during the period under review.

Compliance with agreement terms and applicable laws and regulations

Reviewed, assessed and reported on compliance with the terms and conditions of agreement.

Representations by the management

Obtained specific written representations from management

Contractual obligations

- Appraised relevant documents such as agreement between International Development Association (IDA) and carried out by the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa) and the Federal Democratic Republic of Ethiopia (FDRE) as well as documents concerning rights and obligations with a view to providing a comprehensive appraisal of the project;
- Verified compliance of project expenditures with relevant terms of agreements as well as all the applicable rules;
- Verified compliance of the recipient with the terms and conditions of the agreement with the donor; and
- Ensured timely submission of interim unaudited financial reports for the project as stipulated in the agreement.

Receipts and disbursements

Verified compliance with the disbursements and procurement procedures set up for CDT-Africa.

Implementation

- Examined whether expenditures are classified in accordance with the budget;
- Reviewed bank statements and other relevant books of accounts and assessed whether they show a complete view of the income received and expenditure incurred in accordance with generally accepted principles;
- Verified and confirmed that all commitments are genuine, with the relevant agreements disclosed within the financial records and are for the pursuance of agreed Project objectives;
- Examined a representative sample of payments transactions of and within the Project including accuracy and completeness of records; and
- Verified individual CDT-Africa accounts and gave an opinion and/ or advice regarding the manner they are operated.

Other income sources

- Established whether other income, if any, generated by CDT-Africa, such as interest, in-kind/local contributions, exchange gains, etc.; have been used in furtherance of the Project objectives; and
- Verified that contributions made towards CDT-Africa activities were made and used in accordance with relevant agreement.

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

1.6 Results of the audit

1.6.1 Summary of results by audit objectives

- (i) Reach an opinion as to the validity of the statement of receipts and expenditure and the statement of financial position of CDT-Africa.

In our opinion, the special purpose financial statement referred to above give a true and fair view of the cash receipts and expenditure and the balance of CDT-Africa fund and cash status in accordance with the accounting policies set out on note 3.3 and in conformity with the grant agreement.

- (ii) Report on the financial management and internal controls

We reviewed the internal control structure and concluded that the system was adequate to meet the needs of CDT-Africa.

- (iii) Report on the compliance with agreement terms and applicable laws and regulations.

The results of our tests disclosed no instance of non-compliance as discussed in Section 4 of this report.

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

2 STATEMENTS OF MANAGEMENT'S RESPONSIBILITIES

The Management of the CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA) is responsible for preparing the CDT-Africa financial statements for the period which gives a true and fair view of the state of affairs of the preservation and valorization of the project for the period from July 8, 2021 to July 7, 2022. The Management is required to ensure the project keeps proper accounting records which disclose with reasonable accuracy at any time the financial position of the project. The Management is also responsible for safeguarding the assets of the project.

The Management of the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa) is responsible for preparing the CDT-Africa financial statements that give a true and fair view in accordance with the accounting policy stated in section 2.1 of this report and for such internal controls as the management determine are necessary to enable the preparation of CDT-Africa financial statement are free from material misstatement, whether due to fraud or error.

The Management of CDT- AFRICA accepts responsibility for the CDT-Africa financial statement which has been prepared using appropriate accounting policies supported by reasonable and prudent judgments and estimates. The Management of CDT- AFRICA is of the opinion that CDT-Africa financial statement give a true and fair view of the state of the financial affairs of CDT-Africa and of the results of its activities. The Management of CDT- AFRICA further accepts responsibility for the maintenance of accounting records which may be relied upon in the preparation of the CDT-Africa financial statements, as well as adequate systems of internal financial control.

- i) Designing, implementing and maintaining such internal control as they determine necessary to enable the presentation of financial statements that are free from material misstatement, whether due to fraud or error;
- ii) Selecting suitable accounting policies and applying them consistently; and
- iii) Making accounting estimates and judgements that are reasonable in the circumstances.

The Management certifies that, to the best of its knowledge, the information furnished to the auditors for the audit was correct and is an accurate presentation of the Project's financial transactions.

Management acknowledges that the independent audit of the financial statements does not relieve them of their responsibilities.

Nothing has come to the attention of Management to indicate that the Project will not remain a going concern for at least the next twelve months from the date of this statement.

Signed on behalf of the management by:



Prof. Abebaw Fekadu
Center leader



Tesfaye Asefa, Senior Finance Officer,
CDT-Africa College of Health Sciences,
Addis Ababa University

04 January 2023



Chartered Certified Accountants and Authorized Auditors
የተመሰከረላቸው የሂሳብ አዋቂዎችና የተፈቀደላቸው አዲተሮች

HST General Partnership
Ethio-China Avenue; Wollo Sefer
Mina Building 5th Floor
P.O. Box 1608
Addis Ababa
Ethiopia

Tel.: +251 115 527666/67
Fax.: +251 115 528384
Email: info@hst.et.com
www.hst-et.com

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-
AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022

Engagement

We have audited the statement of Income and Expenditures of Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), for the period from July 8, 2021 - July 7, 2022 concerning the CDT-Africa activities related to Ethiopia.

AUDIT REPORT- Supporting CDT- AFRICA Project.

Opinion

We have audited the accompanying financial statements under the grant agreement concerning the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), which comprise the statement of Income and Expenditure for the period from July 8, 2021- July 7, 2022 and notes to the financial statement, including a summary of significant accounting policies.

In our opinion, the accompanying financial statement give a true and fair view of the income received and expenditure of Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa), for the period from July 8, 2021- July 7, 2022 , and were utilized for the purpose defined in the funding agreement and in accordance with the accounting policies set out in note 2.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statement section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management for the Project Financial Statement

The financial statement, drawn up in accordance with the conditions in the grant agreement dated on June 15, 2016 is the responsibility of the Management of Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa). The Management is responsible for the preparation and fair presentation of the financial statement in accordance with the CDT-Africa's accounting policies set out on note 2; this includes determining that this basis of accounting is an acceptable basis for the preparation of the financial statement in the circumstances, and for such internal controls as management determines is necessary to enable the preparation of the financial statement that is free from material misstatement, whether due to fraud or error.

Auditors' responsibilities for the Audit of the Project Financial Statements

It is our responsibility to issue an opinion on the financial statement, based on our audit. We conducted our audit in accordance with International Auditing Standards (ISAs). This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with laws, regulations, and auditing standards and practices generally accepted in Ethiopia, including International Standards on Auditing (ISA 800/805), we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The engagement partner on the audit resulting in this independent auditors' report is Thomas Mulugeta

HST

Thomas Mulugeta
Partner

HST General Partnership, Chartered Certified Accountants and Authorized Auditors
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa)
Addis Ababa, Ethiopia
04 January 2023



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
STATEMENT OF FINANCIAL POSITION
FOR THE PERIOD ENDED 7 JULY 2022

		2022	2021
	Note	ETB	ETB
Asset			
Current asset			
DEBTORS AND PREPAYMENTS	3	11,894,036	16,897,244
CASH	4	97,952,725	109,856,597
Total Asset		109,846,761	126,753,841
Fund and liabilities			
Fund		109,539,222	125,576,621
Total fund		109,539,222	125,576,621
Current liabilities			
Other liability	5	307,538	1,177,220
Total liabilities		307,538	1,177,220
Total fund and liabilities		109,846,761	126,753,841

The financial statements on pages 10 to 17 were approved and authorized for issue by the management on January 04, 2023 and were signed on its behalf by:



Prof. Abebaw Fekadu
Center leader



Tesfaye Asefa,
Senior Finance Officer, CDT-Africa College of
Health Sciences, Addis Ababa University



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA)
STATEMENT OF INCOME AND EXPENDITURE
FOR THE PERIOD ENDED 7 JULY 2022

	Note	2022 ETB	2021 ETB
INCOME			
Grant	6	76,001,281	88,628,405
Other income	7	15,535,068	20,574,734
		91,536,349	109,203,139
EXPENDITURE	8	107,573,747	60,448,182
Excess of income over expenditure		(16,037,398)	48,754,957



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
STATEMENT OF CHANGES IN FUND BALANCES
FOR THE PERIOD ENDING JULY 07, 2022

	Note	General Fund ETB
As at JULY 8,2021	14	125,576,621
Excess of expenditure over income		(16,037,398)
As at 7 JULY 2022		109,539,222



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA).
STATEMENT OF DESIGNATED ACCOUNT-WORLD BANK
FOR THE PERIOD ENDED 7 JULY 2022

IDA CREDIT

Account Number
Depository Bank
Related Credit and Grant
Address
Currency

100171300038
National Bank of Ethiopia
IDA Loan number: IDA57940 and Project ID No. P151847
Addis Ababa
USD

	7 July 2022		7 July 2021	
	USD	ETB	USD	ETB
Balance Brought forward	1,066,486	46,747,479	1,070,714	37,519,647
Add: Transferred from World Bank-Credit	590,380	30,490,887	1,153,450	44,791,019
Reimbursement from Advance payment/Other	15,904	812,151	-	-
Total	1,672,770	78,050,517	2,224,165	82,310,666
Less: Transfer to Birr account & other Expenditure	(941,292)	(46,558,834)	(1,157,679)	(46,566,575)
Add: Gain on exchange	-	6,618,538	-	11,003,388
Ending Balance July 07, 2022	731,478	38,110,221	1,066,486	46,747,479



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC
TRIALS FOR AFRICA (CDT-AFRICA)

FOR THE PERIOD ENDED 7 JULY 2022

ACCOUNTING POLICIES

2 BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

CDT-AFRICA follows the government's accounting policy of modified cash basis of accounting system. Where, the cash basis of accounting applies except for:-

-Revenue and expenditure recognition when aid in kind is received.

2.2 Income and expenditure

Income and expenditure are recognized on modified cash basis of accounting. Income is recognized when cash is received from IDA and other sources of funds, and expenses are recognized when paid.

2.1.1 Expenditure is recognised: -

- (i) When PAYROLL is processed, When goods are received, or services are rendered and if payments were affected in advance for the goods or services rendered.
- (ii) Salary related transactions withholdings, VAT and withholding from suppliers are recognised in the absence of actual cash transaction.
- (iii) Advance payments are recorded as receivable and charged to expenditure account against valid supporting documents which show the receipt of goods or services or accomplishments of the purpose of the advance.
- (iv) Accounting for direct payments will be charged to expenditure.
- (v) All other revenues and expenditures are recognized as per cash basis of accounting i.e., revenues and expenditures are recognized, when cash is received and paid respectively.
- (vi) Fixed Asset purchases are charged to expenses up on purchase & recorded on the Fixed Asset Register Book.

2.3 Currency transactions

Transactions are mainly incurred in Ethiopian Birr.

2.4 GRANT


Grant income

Grants are funds provide to support general operations and program activities of the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa). And are given to help the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa) to develop and maintain the necessary capacity to achieve its wider mandate.



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022
ACCOUNTING NOTE

	2022	2021
	ETB	ETB
3 DEBTORS AND PREPAYMENTS		
Advances to Supplier	11,481,935	14,666,901
Other Advance	212,742	1,001,025
Advances to Staff	199,359	1,229,318
	11,894,036	16,897,244
4 CASH		
Donors Account balance-NBE	53,044,421	57,343,859
Designated Account-NBE	38,058,599	46,747,479
NBE-Birr Account	6,849,705	5,765,259
	97,952,725	109,856,597
5 PAYABLES		
Other payables within gov't	-	983,130
Retention payable	307,538	194,090
	307,538	1,177,220
6 Grant/ Donation		
6.1 IDA Grant		
IDA	30,490,887	44,791,019
6.2 Other grants		
Kings' College London Asset	14,813,205	2,975,470
Kings' College London SPARK	5,815,106	-
UHEP-Welcome Trust	5,372,078	-
PTSD PROJECT	3,760,782	-
University of Sussex-BSMS (End point 2)	3,725,928	-
BC-Ethiopia PROJECT FUND	1,832,562	-
MUTUAL PROJECT FUND	1,755,257	-
NC4 AHOP	1,641,209	7,700,929
EDCTP-Prazopt	1,434,736	430,181
University of Sussex - IMPRESS	1,245,864	3,005,594
NIMR-EDCTP EXIT TB	1,028,399	4,038,358
Right Fun-BIOSQUARE	800,386	-
EDCTP-PROFORMA	797,720	958,394
University of Sussex-BSMS (End point 1)	757,911	-
King's College London IPV	729,252	-
CLINOPS MBG FOUNDATION	-	24,679,821
NIMR	-	48,638
TAT-SAFE	-	-
EDCTP-EACCR2	-	-
	76,001,281	88,628,405



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022
ACCOUNTING NOTE

7	OTHER INCOME	2022 ETB	2021 ETB
	Foreign exchange gain		
	Foreign Exchange Gain	15,535,068	11,003,388
	External Generated Revenues	-	9,571,346
		15,535,068	20,574,734
8	EXPENDITURE		
8.1	Expenditure Classification (IDA Fund)		
	Research Excellence	31,737,075	17,132,787
	Well functioning CDT-Africa Consortium	12,812,938	9,191,375
	Learning excellence	5,115,681	4,365,888
	Ensure best procurement practice	262,844	-
	Quality Assurance	224,876	593,358
	Adhere to best financial management practice	128,800	112,700
	Strengthen education & research capacity	-	174,616
		50,282,214	31,570,725
8.2	Expenditure from other grants		
	ClinOps project-Bill & Melinda bates Foundation Fund	16,039,320	2,320,790
	CDT-AFRICA-King's College London (ASSET Project)	13,926,443	8,232,741
	CDT-AFRICA-University of Sussex -BSMS (Endpoint project)	6,397,532	5,502,520
	CDT-Africa-London School of Economics & Political Sciences	3,689,471	3,364,096
	SPARK Project Fund	2,543,673	-
	CDT-AFRICA-University of Sussex -BSMS (Endpoint 2 project)	2,514,598	-
	CDT-AFRICA-EDCTP-EXIT-TB	2,187,698	3,104,992
	CDT-AFRICA-EDCTP Prazopt	1,944,952	242,159
	MUTUAL Project	1,630,146	-
	UHEP-Wellcome Trust Fund	1,625,301	391,530
	CDT-AFRICA-EDCTP-PROFORMA	876,321	329,738
	CDT-Africa-University of Sussex- BSMS (IMPRESS Project)	795,596	2,780,544
	BC ETHIOPIA Project Fund	770,088	-
	CDT-AFRICA-King's College London (IPV Project)	746,461	1,120,683
	PTSD Project Fund	629,652	-
	CDT-AFRICA-EDCTP-EXIT-TB (TB-node)	566,922	86,305
	VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	291,818	581,321
	CDT-AFRICA-EDCTP-EACCR-2 (Uganda Virus Research Institute)	113,943	228,439
	Right fund	1,600	591,600
		57,291,533	28,877,457
		107,573,747	60,448,182



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022
NOTES TO STATEMENT OF FUND BALANCE

14 Source of Funds	Balance brought Forward	Received	FC Gain/Loss	Expense	Balance carried Forward
IDA & Other source	66,303,503	30,490,887	6,618,538	(50,282,214)	53,130,714
Kings College London (ASSET)	9,557,768	14,813,205	1,258,123	(13,926,443)	11,702,652
The University of Sussex, Brighton (ENDPOINT)	7,701,703	757,911	657,543	(6,397,532)	2,719,625
Karolinska Instituted , Stockholm (PROFORMA)	1,253,399	797,720	40,552	(876,321)	1,215,349
Uganda Virus Research Institute (EACCR 2)	529,800	-	80,221	(113,943)	496,078
EDCTP-EXIT TB-TB node	1,020,981	-	23,190	(566,922)	477,249
National Institute for Medical Research (EXIT-TB)	3,462,925	1,028,399	79,143	(2,187,698)	2,382,770
Kings' college London (IPV)	1,128,257	729,252	181,262	(746,461)	1,292,310
EDCTP-Prapopt Grant	4,660,344	1,434,736	102,404	(1,944,952)	4,252,532
VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	489,865	-	26,721	(291,818)	224,767
IMPRESS Project Grant	404,966	1,245,864	69,605	(795,596)	924,838
AHOP NC 4: Ethiopia Project Grant	6,481,196	1,641,209	1,083,989	(3,689,471)	5,516,922
ClinOps Project- BILL & MELLNDA Gates Foundation Fund	23,565,046	-	3,174,924	(16,039,320)	10,700,649
UHEP-Welcome Trust Fund	(391,530)	5,372,078	505,058	(1,625,301)	3,860,306
SPARK Project Fund	-	5,815,106	930,531	(2,543,673)	4,201,963
Right Fund	(591,600)	800,386	32,868	(1,600)	240,054
PTDS Project Fund	-	3,760,782	556,645	(629,652)	3,687,775
Mutual Project Fund	-	1,755,257	48,737	(1,630,146)	173,848
BC ETHIOPIA Project Fund	-	1,832,562	53,243	(770,088)	1,115,718
The University of Sussex, Brighton (ENDPOINT) 2	-	3,725,928	11,771	(2,514,598)	1,223,102
Total	125,576,621	76,001,281	15,535,068	(107,573,747)	109,539,222





Chartered Certified Accountants and Authorized Auditors

የተመሰከረላቸው የሂሳብ አዋቂዎችና የተፈቀደላቸው አዲተሮች

HST General Partnership
Ethio-China Avenue; Wollo Sefer
Mina Building 5th Floor
P.O. Box 1608
Addis Ababa
Ethiopia

Tel.: +251 115 527666/67
Fax.: +251 115 528384
Email: info@hst.et.com
www.hst-et.com

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022
ADDIS ABABA

Attention:
Country Director

Dear Sir,

4 INDEPENDENT AUDITORS' REPORT ON COMPLIANCE IN RELATION WITH DISBURSEMENT OF INDICATOR/RESULTS (DLI/DLR)

We have performed audit procedures to ascertain that disbursements in relation to Indicator/Results (DLI/DLR) and the funds released there to are in line with the requirements of the Eligible Expenditure programs for the period from July 8, 2021 to July 7, 2022.

We conducted our audit in accordance with International Standards on Auditing. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the statement of receipts and expenditure is free of material misstatement resulting from violations of agreement terms and laws and regulations that have a direct and material effect on the determination of the statement of receipts and expenditure amounts. During the audit, we performed procedures with special attention to;

- a) Disbursements linked with Indicators/Results as defined in the financial agreements have been achieved
- b) Eligible Expenditure program submitted to the Bank for reimbursement are fairly stated, complete and reliable
- c) Goods, services and works financed that have been procured in accordance with specific provisions of the World Bank policies and procedures of procurements and the relevant financing agreement
- d) Necessary supporting documents, records and accounts have been maintained in respect of all project activities and reported statements of expenditures.
- e) Proper maintenance of designated bank accounts of projects in accordance of the provisions of the relevant financing agreements and proper use of the funds disbursed out of the accounts.
- f) Compliance with national laws and regulations
- g) Any assets procured from the project funds

Compliance with agreement terms, laws and regulations, contracts and binding policies and procedures are the responsibility of the Management of the Project. As part of our audit, we selected and tested transactions and records in relation to the EEP, to determine the project's compliance with agreement terms, laws, regulations, contracts, binding policies and procedures.

Material instances of non-compliance are failure to follow requirements or violations of agreement terms and laws and regulations that cause us to conclude that the aggregation of misstatements resulting from those failures or violations is material to the fund accountability statement.

Our consideration and evaluation of transactions tested did not reveal any significant instances of non-compliance in relation to funds disbursed to AAU-CDT and in accordance with the financing agreement, laws and regulations.

This report is intended for the information of the Management of the International Development Association (IDA).

The engagement partner on the audit resulting in this independent auditors' report is Thomas Mulugeta.

Thomas Mulugeta
Partner

HST General Partnership, Chartered Certified Accountants and Authorized Auditors
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa)
Addis Ababa
04 January 2023



Chartered Certified Accountants and Authorized Auditors

የተመሰከረላቸው የሂሳብ አዋቂዎችና የተፈቀደላቸው አዲተሮች

HST General Partnership
Ethio-China Avenue; Wollo Sefer
Mina Building 5th Floor
P.O. Box 1608
Addis Ababa
Ethiopia

Tel.: +251 115 527666/67
Fax.: +251 115 528384
Email: info@hst.et.com
www.hst-et.com

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND
THERAPEUTIC TRIALS FOR AFRICA (CDT-AFRICA)
FOR THE PERIOD ENDED 7 JULY 2022
ADDIS ABABA

Attention:
Center leader

Dear Sir,

5 INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL

We have audited the accompanying financial statements of Project set out on pages 10 to 17, which includes Statement of Receipts and Expenditure for the period July 8, 2021- July 7, 2022 and the related notes to the financial statement, including summary of significant accounting policies.

We conducted our audit in accordance with International Standards on Auditing. In planning and performing our audit, we considered the CDT-Africa's internal control over financial reporting as a basis for designing our auditing procedures for expressing our opinion on the statement of receipts and expenditure, but not for expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we do not express an opinion on the effectiveness of the entity's internal control.

Our consideration of internal control was for the limited purpose described in the preceding paragraph and was not designed to identify all deficiencies in internal control that might be significant deficiencies or material weaknesses and therefore, there can be no assurance that all deficiencies, significant deficiencies, or material weaknesses have been identified.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the project's fund accountability statement will not be prevented, or detected and corrected on a timely basis.

Based on our audit, we did not identify any deficiencies to report on.

This report is intended for the information of the International Development Association (IDA).

The engagement partner on the audit resulting in this independent auditors' report is Tomas Mulugeta.

Thomas Mulugeta
Partner

HST General Partnership, Chartered Certified Accountants and Authorized Auditors
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT- Africa)
Addis Ababa
04 January 2023

CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA), ADDIS ABABA UNIVERSITY
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (P151847-IDA57940)
STATEMENT OF SOURCES & USES OF FUNDS (BIRR)
FOR THE PERIOD ENDING JULY 07, 2022

Source of Funds	Semi-Annual period Ending Jan. 08, 2022	Semi-Annual period Ending July 07, 2022	Commutative For year End of July 07, 2022
OPENING CASH BALANCE (BBF)			
Government Funds	-	-	-
World Bank IDA Funds	66,303,503	55,138,749	66,303,503
Student Fees	-	-	-
Others	-	-	-
TOTAL OPENING BALANCE-WORLD BANK IDA FUND [A]	66,303,503	55,138,749	66,303,503
ADD: RECEIPTS:			
Government Funds	-	-	-
World Bank IDA Funds	-	30,490,887	30,490,887
Student Fees	-	-	-
Others (advance collections)	-	-	-
TOTAL CURRENT PERIOD RECEIPT-IDA & Other source [A']	-	30,490,887	30,490,887
EXTERNALLY GENERATED REVENUES : OPENING FUND BALANCE (BALANCE)			
CDT-AFRICA- University of Sussex -BSMS (EndPoint project) Grant-1	7,701,703	2,321,010	7,701,703
CDT-AFRICA-King's College London (ASSET Project) Grant-2	9,557,768	7,094,341	9,557,768
CDT-AFR-CA-EDCTP-PROFORMA Grant-3	1,253,399	1,527,067	1,253,399
CDT-AFRICA-EDCTP-EACCR-2 (Uganda Virus Research Institute) Grant-4	529,800	470,483	529,800
CDT-AFRICA-EDCTP-EXIT-TB (TB-node) Grant-5	1,020,981	499,486	1,020,981
CDT-AFRICA-EDCTP-NIMR-EXIT-TB Grant	3,462,925	2,374,032	3,462,925
CDT-AFRICA-King's College London (IPV Project) Grant	1,128,257	1,454,874	1,128,257
CDT-AFRICA-EDCTP-Prazopt Grant	4,660,344	5,224,551	4,660,344
CDT-AFRICA-VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	489,865	215,926	489,865
CDT-Africa-University of Sussex- BSMS (IMPRESS Project)	404,966	(296,317)	404,966
CDT-Africa-London School of Economics & Political Sciences (AHOP NC4: Ethiopia project)	6,481,196	5,873,740	6,481,196
ClinOps Project- BILL & MELLNDA Gates Foundation Fund	23,565,046	20,283,892	23,565,046
UHEP-Wellcome Trust Fund	(391,530)	4,633,955	(391,530)
SPARK Project Fund	-	6,302,209	-
Right Project Fund	(591,600)	229,974	(591,600)
PTSD Project Fund	-	4,069,618	-
MUTUAL Project Fund	-	499,745	-
BC Ethiopia Project Fund	-	905,029	-
CDT-AFRICA-University of Sussex -BSMS (EndPoint project) 2 Grant	-	(369,240)	-
EXTERNALLY GENERATED REVENUES :TOTAL OPENING FUND BALANCE (B)	59,273,118	63,314,376	59,273,118
EXTERNALLY GENERATED REVENUES :CURRENT PERIOD RECEIPT			
University of Sussex -BSMS (EndPoint project) Grant	-	757,911	757,911
King's College London (ASSET Project) Grant	5,347,221	9,465,984	14,813,205
CDT-AFR-CA-EDCTP-Karolinska Institute-PROFORMA Grant	797,720	-	797,720
CDT-AFRICA-EDCTP-EACCR-2 (Uganda Virus Research Institute) Grant	-	-	-
CDT-AFRICA-EDCTP-NIMR-EXIT-TB Node Grant	-	-	-
CDT-AFRICA-EDCTP-NIMR-EXIT-TB Grant	550,857	477,542	1,028,399
CDT-AFRICA-King's College London (IPV Project) Grant	729,252	-	729,252
CDT-AFRICA-EDCTP-Prazopt Grant	1,434,736	-	1,434,736
CDT-AFRICA-VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	-	-	-
CDT-Africa-University of Sussex- BSMS (IMPRESS Project)	-	1,245,864	1,245,864
CDT-Africa-London School of Economics & Political Sciences (AHOP NC4: Ethiopia project)	-	1,641,209	1,641,209
ClinOps Project- BILL & MELLNDA Gates Foundation Fund	-	-	-
UHEP-Wellcome Trust Fund	5,372,078	-	5,372,078
SPARK Project Fund	5,815,106	-	5,815,106
Right Project Fund	800,386	-	800,386
PTSD Project Fund	3,760,782	-	3,760,782
MUTUAL Project Fund	742,200	1,013,057	1,755,257
BC Ethiopia Project Fund	878,051	954,511	1,832,562
CDT-AFRICA-University of Sussex -BSMS (EndPoint project) 2 Grant	-	3,725,928	3,725,928




CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA), ADDIS ABABA UNIVERSITY
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (P151847-IDA57940)
STATEMENT OF SOURCES & USES OF FUNDS (BIRR)
FOR THE PERIOD ENDING JULY 07, 2022

Source of Funds	Semi-Annual period Ending Jan. 08, 2022	Semi-Annual period Ending July 07, 2022	Cumulative For year End of July 07, 2022
EXTERNALLY GENERATED REVENUES : TOTAL CURRENT PERIOD RECEIPT (C)	26,228,388	19,282,005	45,510,394
Gain on exchange of foreign currency-University of Sussex- BSMS (EndPoint project) Grant	524,399	133,144	657,543
Gain on exchange of foreign currency-King's College London (ASSET Project) Grant	880,623	377,500	1,258,123
Gain on exchange of foreign currency-EDCTP-PROFORMA Grant	97,043	(56,491)	40,552
Gain on exchange of foreign currency-EACCR-2 (Uganda Virus Research Institute) Grant	54,627	25,594	80,221
Gain on exchange of foreign currency-EXIT-TB (TB-node) Grant	45,427	(22,237)	23,190
Gain (Loss) on exchange of foreign currency-EDCTP-EXIT TB Grant	199,004	(119,861)	79,143
Gain on exchange of foreign currency-King's College London (IPV Project) Grant	116,329	64,933	181,262
Gain on exchange of foreign currency-EDCTP-Prazopt Grant	314,651	(212,247)	102,404
Gain on exchange of foreign currency-VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	17,879	8,841	26,721
Gain on exchange of foreign currency-University of Sussex- BSMS (IMPRESS Project) grant	16,294	53,310	69,605
Gain on exchange of foreign currency- (AHOP NC4: Ethiopia project) grant	726,827	357,163	1,083,989
Gain on exchange of foreign currency-ClinOps Project- BILL & MELLNDA Gates Foundation Fund	2,402,779	772,145	3,174,924
Gain on exchange of foreign currency- UHEP-Wellcome Trust Fund	276,557	228,501	505,058
Gain on exchange of foreign currency- SPARK Project Fund	616,026	314,505	930,531
Gain on exchange of foreign currency- Right Project Fund	22,788	10,080	32,868
Gain on exchange of foreign currency- PTSD Project Fund	346,549	210,096	556,645
Gain on exchange of foreign currency- MUTUAL Project Fund	24,146	24,591	48,737
Gain on exchange of foreign currency- BC Ethiopia Project Fund	26,978	26,266	53,243
Gain on exchange of foreign currency-University of Sussex- BSMS (EndPoint project) 2 Grant	-	11,771	11,771
Total Gain on exchange of foreign currency (D)	6,708,927	2,207,603	8,916,530
TOTAL EXTERNALLY GENERATED REVENUES [E] = B+C+D	92,210,433	84,803,985	113,700,041
(Gain on exchange of Foreign currency-WB FUND) Semi-Annual period ending January 08, 2022 [F]	4,978,195	1,640,343	6,618,538
TOTAL FINANCING FROM WORLD BANK FUND [A+A'+F]= G	71,281,698	87,269,979	103,412,928
GRAND TOTAL FINANCING FROM WORLD BANK & EXTERNALLY GENERATED REVENUES [E+G] = H	163,492,130	172,073,964	217,112,970
LESS: ACE Expenditure as per project Implementation plan			
EXPENDITURE CLASSIFICATION 1			
Well functioning CDT-Africa Consortium	4,704,455	8,108,483	12,812,938
EXPENDITURE CLASSIFICATION 2			
Learning excellence	2,186,129	2,929,552	5,115,681
EXPENDITURE CLASSIFICATION 3			
Research Excellence	8,913,765	22,823,311	31,737,075
EXPENDITURE CLASSIFICATION 4			
Quality assurance	209,801	15,075	224,876
EXPENDITURE CLASSIFICATION 5			
Strengthen education & research capacity	-	-	-
EXPENDITURE CLASSIFICATION 6			
Adhere to best financial management practice	128,800	-	128,800
EXPENDITURE CLASSIFICATION 7			
Ensure best procurement practice	-	262,844	262,844
TOTAL USE OF FUND BY COMPONENT-WORLD BANK FUND [I]	16,142,949	34,139,265	50,282,214
EXPENDITURES ON EXTERNALLY GENERATED REVENUES			
CDT-AFRICA-University of Sussex- BSMS (EndPoint project) Grant	5,905,091	492,440	6,397,532
CDT-AFRICA-King's College London (ASSET Project) Grant	8,691,271	5,235,173	13,926,443
CDT-AFRICA-EDCTP-EACCR-2 (Uganda Virus Research Institute) Grant	113,943	-	113,943
CDT-AFRICA-EDCTP-EXIT-TB (TB-node) Grant	566,922	-	566,922
CDT-AFRICA-EDCTP (PROFORMA) Grant	621,096	255,226	876,321
CDT-AFRICA-EDCTP (EXIT-TB) Grant	1,838,754	348,943	2,187,698
CDT-AFRICA-EDCTP (Prazopt) Grant	1,185,179	759,772	1,944,952
CDR-AFRICA-Kings college London (IPV Project) Grant	518,965	227,496	746,461
VINS Bioproducts LTD-Clinical Study of TAT Safe Grant	291,818	-	291,818
CDT-Africa-University of Sussex- BSMS (IMPRESS Project)	717,576	78,020	795,596



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA), ADDIS ABABA UNIVERSITY
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE- PROJECT (P151847-IDA57940)
STATEMENT OF SOURCES & USES OF FUNDS (BIRR)
FOR THE PERIOD ENDING JULY 07, 2022

Source of Funds	Semi-Annual period Ending Jan. 08, 2022	Semi-Annual period Ending July 07, 2022	Commulative For year End of July 07, 2022
CDT-Africa-London School of Economics & Political Sciences (AHOP NC4: Ethiopia project)	1,334,282	2,355,189	3,689,471
ClinOps Project- BILL & MELLNDA Gates Foundation Fund	5,683,933	10,355,387	16,039,320
UHEP-Wellcome Trust Fund	623,150	1,002,150	1,625,301
SPARK Project Fund	128,923	2,414,750	2,543,673
Right Project Fund	1,600	-	1,600
PTSD Project Fund	37,713	591,938	629,652
MUTUAL Project Fund	266,601	1,363,545	1,630,146
BC Ethiopia Project Fund	-	770,088	770,088
CDT-AFRICA-University of Sussex -BSMS (EndPoint project) 2 Grant	369,240	2,145,358	2,514,598
TOTAL EXPENDITURES ON EXTERNALLY GENERATED GRANT [J]	28,896,057	28,395,476	57,291,533
GRAND TOTAL EXPENDITURES [J+J] = K	45,039,006	62,534,741	107,573,747
GRAND TOTAL CLOSING BALANCE [H-K]	118,453,124	109,539,222	109,539,222
Government Funds	-	-	-
WORLD BANK- IDA Funds (Balance on Foreign currency Birr Account)	33,480,239	38,058,599	38,058,599
Receivables on Foreign currency Birr Account (Advance to supplier) & Other Receivables (WORLD BANK FUND)	19,087,484	10,993,736	10,993,736
Cash Balance on Designated Birr Account (WORLD BANK FUND)	2,627,902	4,359,373	4,359,373
Payables on Designated Birr Account (WORLD BANK FUND)	(56,876)	(280,993)	(280,993)
TOTAL CLOSING CASH BALANCE (WORLD BANK FUND) [L]	55,138,749	53,130,714	53,130,714
EXTERNALLY GENERATED REVENUES CLOSING CASH BALANCE			
CDT-AFRICA-BSMS (EndPoint 1 project) Grant (Balance on Foreign currency Sub-Ledger Birr Account)	2,320,307	2,739,920	2,739,920
CDT-AFRICA-KING'S COLLEGE LONDON-ASSET PROJECT Grant (Balance on Foreign currency Sub-Ledger Birr Account)	5,635,512	10,364,535	10,364,535
CDT-AFRICA-EDCTP-PROFORMA Project Grant (Balance on Foreign currency Sub-Ledger Birr Account)	1,450,829	1,131,424	1,131,424
CDT-AFRICA-EDCTP- (EACCR-2) Grant- UVRI (Balance on Foreign currency Sub-Ledger Birr Account) (EDCTP)	465,435	491,029	491,029
CDT-AFRICA EDCTP-EXIT-TB (TB-node) Grant (Balance on Foreign currency Sub-Ledger Birr Account)	463,153	440,916	440,916
CDT-AFRICA EDCTP-EXIT-TB Grant (Balance on Foreign currency Sub-Ledger Birr Account)	2,407,219	2,381,979	2,381,979
CDT-AFRICA-KING'S COLLEGE LONDON-IPV PROJECT Grant(Balance on Foreign currency Sub-Ledger Birr Account)	1,246,978	1,159,461	1,159,461
CDT-AFRICA-EDCTP-PRAZOPT Project Grant (Balance on Foreign currency Sub-Ledger Birr Account)	5,014,762	4,162,910	4,162,910
CDT-AFRICA- VINS Bioproducts LTD-Clinical Study of TAT Safe Grant(Balance on Foreign currency Sub-Ledger Birr Account)	160,776	169,617	169,617
CDT-AFRICA University of Sussex- BSMS (IMPRESS Project) grant (Balance on Foreign currency Sub-Ledger Birr Account)	21	891,396	891,396
CDT AFRICA-(AHOP NC4: Ethiopia project) grant (Balance on Foreign currency Sub-Ledger Birr Account)	5,790,489	5,379,662	5,379,662
CDT Africa-ClinOps Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	18,294,102	10,360,957	10,360,957
CDT Africa-UHEP-Wellcome Trust Fund (Balance on Foreign currency Sub-Ledger Birr Account)	4,488,503	3,694,733	3,694,733
CDT Africa-SPARK Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	6,237,765	4,063,086	4,063,086
CDT Africa-Right Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	183,305	193,385	193,385
CDT Africa-PTSD Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	3,959,669	3,501,026	3,501,026
CDT Africa-MUTUAL Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	526,102	171,622	171,622
CDT Africa BC Ethiopia Project Fund (Balance on Foreign currency Sub-Ledger Birr Account)	905,029	1,103,134	1,103,134
CDT-AFRICA-University of Sussex -BSMS (EndPoint project) 2 Grant (Balance on Foreign currency Sub-Ledger Birr Account)	-	643,631	643,631
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Receivables (ENDPOINT PROJECT GRANT)	0	-	-



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA), ADDIS ABABA UNIVERSITY
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (P151347-IDA57940)

STATEMENT OF SOURCES & USES OF FUNDS (BIRR)
FOR THE PERIOD ENDING JULY 07, 2022

Source of Funds	Semi-Annual period Ending Jan. 08, 2022	Semi-Annual period Ending July 07, 2022	Commutative For year End of July 07, 2022
Cash Balance on Designated Sub- Ledger BIRR Account (ENDPOINT PROJECT GRANT)	30,927	3,776	3,776
Payables on Designated BIRR Account (ENDPOINT PROJECT GRANT)	(30,224)	(24,071)	(24,071)
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (ASSET PROJECT Grant)	1,073,350	900,300	900,300
Cash Balance on Designated BIRR Account (ASSET PROJECT Grant)	392,438	437,817	437,817
Payables on Designated BIRR Account (ASSET PROJECT Grant)	(6,960)	-	-
Receivables on Foreign currency /BIRR Account (Travel Advance) & Other Recivables (PROFORMA Grant)	-	-	-
Cash Balance on Designated BIRR Account (PROFORMA Grant)	76,238	83,926	83,926
Payables on Designated BIRR & EUR Account (PROFORMA Grant) to Endpoint project	-	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (EACCR-2 Grant)	-	-	-
Cash Balance on Designated Sub- Ledger BIRR Account (EACCR-2 Grant)	9,996	7,522	7,522
Payables on Designated BIRR Account (EACCR-2 Grant)	(4,948)	(2,474)	(2,474)
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (EXIT-TB- TB node Grant)	-	-	-
Cash Balance on Designated BIRR Account (EXIT-TB- TB node Grant)	76,323	36,333	36,333
Payables on Designated BIRR Account (EXIT-TB- TB node Grant)	(39,990)	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (EXIT-TB- Grant)	-	-	-
Cash Balance on Designated BIRR Account (EXIT-TB- Grant)	32,036	791	791
Payables on Designated BIRR Account (EXIT-TB Grant)	(65,222)	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (IPV Grant)	5,530	-	-
Cash Balance on Designated BIRR Account (IPV- Grant)	202,366	132,849	132,849
Payables on Designated BIRR Account (IPV Grant)	-	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (Prazopt Grant)	7,720	-	-
Cash Balance on Designated BIRR Account (Prazopt- Grant)	202,069	89,622	89,622
Payables on Designated BIRR Account (Prazopt Grant)	-	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (TAT Safe- Grant)	-	-	-
Cash Balance on Designated BIRR Account (TAT Safe-Grant)	55,151	55,151	55,151
Payables on Designated BIRR Account (TAT Safe- Grant)	-	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (IMPRESS- Grant)	-	-	-
Cash Balance on Designated BIRR Account (IMPRESS-Grant)	-	33,443	33,443
Payables on Designated BIRR Account (IMPRESS- Grant)	(296,338)	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (AHOP- Grant)	-	-	-
Cash Balance on Designated BIRR Account (AHOP-Grant)	83,250	137,260	137,260
Payables on Designated BIRR Account (AHOP- Grant)	-	-	-
Receivables on Foreign currency / BIRR Account (Travel Advance) & Other Recivables (BMGF- Grant)	1,855,427	-	-
Cash Balance on Designated BIRR Account (BMGF-Grant)	134,363	339,692	339,692
Payables on Designated BIRR Account (MBGF- Grant)	-	-	-



CENTER FOR INNOVATIVE DRUG DEVELOPMENT AND THERAPEUTIC TRIALS FOR AFRICA (CDT- AFRICA), ADDIS ABABA UNIVERSITY
AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (P151847-IDA57940)
STATEMENT OF SOURCES & USES OF FUNDS (BIRR)

FOR THE PERIOD ENDING JULY 07, 2022

Source of Funds	Semi-Annual period Ending Jan. 08, 2022	Semi-Annual period Ending July 07, 2022	Commutative For year End of July 07, 2022
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (UHEP- Grant)	-	-	-
Cash Balance on Designated Birr Account (UHEP-Grant)	145,452	165,572	165,572
Payables on Designated Birr Account (UHEP- Grant)	-	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (SPARK- Grant)	-	-	-
Cash Balance on Designated Birr Account (SPARK-Grant)	157,184	138,878	138,878
Payables on Designated Birr Account (SPARK- Grant)	(92,740)	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (RIGHT- Grant)	-	-	-
Cash Balance on Designated Birr Account (RIGHT-Grant)	46,669	46,669	46,669
Payables on Designated Birr Account (RIGHT- Grant)	-	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (PTDS- Grant)	-	-	-
Cash Balance on Designated Birr Account (PTDS-Grant)	109,949	186,748	186,748
Payables on Designated Birr Account (PTDS- Grant)	-	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (MUTUAL- Grant)	-	-	-
Cash Balance on Designated Birr Account (MUTUAL-Grant)	23,643	2,227	2,227
Payables on Designated Birr Account (MUTUAL- Grant)	(50,000)	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (BC ETHIOPIA- Grant)	-	-	-
Cash Balance on Designated Birr Account (BC ETHIOPIA-Grant)	-	12,584	12,584
Payables on Designated Birr Account (BC ETHIOPIA- Grant)	-	-	-
Receivables on Foreign currency / Birr Account (Travel Advance) & Other Recivables (ENDPOINT2- Grant)	-	-	-
Cash Balance on Designated Birr Account (ENDPOINT2-Grant)	-	579,470	579,470
Payables on Designated Birr Account (ENDPOINT2- Grant)	(369,240)	-	-
TOTAL EXTERNALLY GENERATED GRANT CLOSING CASH BALANCE [M]	63,314,376	56,408,508	56,408,508
GRAND TOTAL CLOSING BALANCE [L+M]	118,453,124	109,539,222	109,539,222

Prepared by :

Tesfaye Asefa,
Senior Finance Officer, CDT-Africa
College of Health Sciences, Addis Ababa University

Approved by



ADDIS ABABA UNIVERSITY-CDT AFRICA
FIXED ASSET REGISTER FORM-CONSOLIDATED
FOR THE PERIOD END OF JULY 07, 2022

No	Name of Fixed Asset	GRN Number	Acquisition Date	Procured av/IV No	Quantity (pcs)	Unit Price with VAT	Total Price with VAT	Receipt Number	Type of the Asset	Supplier Name	Project Fund/ Grant/	Location/ FA Holder
1	LABORATORY EQUIPMENT	135348-50	31/12/22	474899	1.00	1,482,050	1,482,050	000002	LABORATORY EQUIPMENT	ZALTECH TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
2	Mixer 500 Liter	000106	22/02/2022	747083/69506	1.00	624,413	624,413	000001507	Mixer 500 Liter	Vanali Com Plc	IDA/World Bank/ Fund	CDT Africa Laboratory Team
3	ROTARY EVAPORATOR	000114	03/01/2022	816671	1.00	490,000	490,000	00000174	ROTARY EVAPORATOR	ZAL TECH TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
4	Horizontal Gel Electropho	000147	20/06/2022	816824	1.00	176,000	176,000	00003624	Horizontal Gel Electropho	More Tech Ind. Plc	IDA/World Bank/ Fund	CDT Africa Laboratory Team
5	Vertical Gel Electropho	000147	20/06/2022	816824	1.00	136,000	136,000	00003624	Vertical Gel Electropho	More Tech Ind. Plc	IDA/World Bank/ Fund	CDT Africa Laboratory Team
6	TABLE TOPHIGH SPEED REFRIGERATED MICRO CENTRIFUGE	000148	20/06/2022	816825	1.00	630,000	630,000	00000530	TABLE TOPHIGH SPEED REFRIGERATED MICRO CENTRIFUGE	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
7	MICRO PIPETE STAND UP TO 9 PIPEPTE HOLDER	000148	20/06/2022	816825	10.00	4,800	48,000	00000530	MICRO PIPETE STAND UP TO 9 PIPEPTE HOLDER	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
8	MICRO SPECTROPHOTOMETRY	000148	20/06/2022	816825	1.00	980,000	980,000	00000530	MICRO SPECTROPHOTOMETRY	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
9	COMBO BINDING MACHINE S100	044301	17/11/21	474794	1.00	11,000	11,000	00000062	COMBO BINDING MACHINE S100	MKE STATIONERY COMPUTER EQUIPMENT SANITARY	IDA/World Bank/ Fund	CDT Africa Laboratory Team
10	LATERAL CABINET TWO METAL DOORS	044306	21/12/21	746983/474875	1.00	9,750	9,750	00018048	LATERAL CABINET TWO METAL DOORS	3F FURNITURE FACTORY PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
11	CO7 OFFICE TABLEAND A152 OFFICE CHAIR	044307	28/02/2022	747090/474961	20.00	5,128	102,560	00004139	CO7 OFFICE TABLEAND A152 OFFICE CHAIR	TIGIST TAKELE LEMMA	IDA/World Bank/ Fund	CDT Africa Laboratory Team
12	BROTHER LABEL	044307	31/12/21	747064/474880	2.00	23,000	46,000	00003142	BROTHER LABEL	MADOT TECHNOLOGY	IDA/World Bank/ Fund	CDT Africa Laboratory Team
13	HP LEASERJET PRO M130FN	044307	31/12/21	747064/474880	1.00	30,000	30,000	00003142	HP LEASERJET PRO M130FN	MADOT TECHNOLOGY	IDA/World Bank/ Fund	CDT Africa Laboratory Team
14	HP 27 MONITOR	044307	31/12/21	747064/474880	2.00	28,500	57,000	00003142	HP 27 MONITOR	MADOT TECHNOLOGY	IDA/World Bank/ Fund	CDT Africa Laboratory Team
15	STAPLIZER 5000VA	044307	31/12/21	747064/474880	4.00	17,800	71,200	00003142	STAPLIZER 5000VA	MADOT TECHNOLOGY	IDA/World Bank/ Fund	CDT Africa Laboratory Team
16	Wi-fi Modern	044312	02/09/2022	69513	1.00	4,280	4,280	1680000456	Wi-fi Modern	Ethio Telecom	IDA/World Bank/ Fund	Mr. Tesfaye Asefa
17	Wi-fi Modern	044312	02/09/2022	69513	1.00	4,250	4,250	1680000456	Wi-fi Modern	Ethio Telecom	IDA/World Bank/ Fund	Mr. Getahun Alemu
18	CO7 OFFICE TABLE 1.20 *60	044323	23/03/22	747304/816521	4.00	7,761	31,044	00004345	CO7 OFFICE TABLE 1.20 *60	TIGIST TAKELE LEMMA	IDA/World Bank/ Fund	CDT Africa Laboratory Team
19	AUTOMATIC 3000 STABILIZER	044324	15/4/22	747316/816522	8.00	21,890	175,120	00002158	AUTOMATIC 3000 STABILIZER	TSEGA RETA IMPORTER	IDA/World Bank/ Fund	CDT Africa Laboratory Team
20	STABLIZER AUTOMATIC 5000	044324	15/4/22	747316/816522	4.00	27,300	109,200	00002158	STABLIZER AUTOMATIC 5000	TSEGA RETA IMPORTER	IDA/World Bank/ Fund	CDT Africa Laboratory Team
21	FLEXIBLE MINI KEYBOARD	044329	19/4/22	747328	2.00	2,500	5,000	00004334	FLEXIBLE MINI KEYBOARD	DAYSTAR	IDA/World Bank/ Fund	CDT Africa Laboratory Team
22	HP CORE I7 16 GB RAM 1TB HDD	044335	17/6/22	816822	2.00	147,400	294,800	00004303	HP CORE I7 16 GB RAM 1TB HDD	MADOT TECHNOLOGY	IDA/World Bank/ Fund	Mr. Wondwosen Tensu
23	HP DESKTOP CORE I7	044335	17/6/22	816822	2.00	89,500	179,000	00004303	HP DESKTOP CORE I7	MADOT TECHNOLOGY	IDA/World Bank/ Fund	Mr. Wondwosen Tensu
24	DESKTOP GRAPHIC CARD 4GB	044335	17/6/22	816822	3.00	8,400	25,200	00004303	DESKTOP GRAPHIC CARD 4GB	MADOT TECHNOLOGY	IDA/World Bank/ Fund	Mr. Wondwosen Tensu
25	VOICE RECORDER	044338	17/06/2022	816823	1.00	9,000	9,000	00004306	VOICE RECORDER	MADOT TECHNOLOGY	IDA/World Bank/ Fund	Mr. Wondwosen Tensu
26	OVEN	044345	24/06/22	747373/816804	1.00	9,000	9,000	00005795	OVEN	Abdurahmane Awol Retail Trade of Crockery Cutlery Kitchenutensils	IDA/World Bank/ Fund	CDT Africa Laboratory Team
27	HEATING MANTLE 250 ML	135301	11/02/2021	474598	1.00	2,000	2,000	00000728	HEATING MANTLE 250 ML	EDULAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
28	HEATING MANTLE 500 ML	135301	11/02/2021	474598	1.00	2,000	2,000	00000728	HEATING MANTLE 500 ML	EDULAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
29	HEATING MANTLE2000ML	135301	11/02/2021	474598	1.00	3,900	3,900	00000728	HEATING MANTLE2000ML	EDULAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
30	HEATING MANTLE 1000ML	135303	11/02/2021	474596	1.00	4,830	4,830	00003260	HEATING MANTLE 1000ML	MORE TECH INDUSTRY PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
31	VACUUM PUMP	135310	11/02/2021	474597	1.00	49,500	49,500	00000482	VACUUM PUMP	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
32	REFRACTOMETER PORTABLE DIGITAL	135312	09/09/2021	474592	1.00	12,000	12,000	00003324	REFRACTOMETER PORTABLE DIGITAL	WISE TEAM PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team



ADDIS ABABA UNIVERSITY-CDT AFRICA
FIXED ASSET REGISTER FORM-CONSOLIDATED
FOR THE PERIOD END OF JULY 07, 2022

No	Name of Fixed Asset	GRN Number	Acquisition Date	Procured PV/PV No	Quantity (pcs)	Unit Price with VAT	Total Price with VAT	Receipt Number	Type of the Asset	Supplier Name	Project Fund/ Grant/	Location/ #A Holder
33	WATER BATH	135314	11/03/2021	474752	1.00	8,800	8,800	00001314	WATER BATH	EDULAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
34	HEATING MANTLE 500 ML	135315	09/09/2021	474594	2.00	4,379	8,758	00003259	HEATING MANTLE 500 ML	MORE TECH INDUSTRY PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
35	COMPACT CENTRIFUGAL	135316	11/02/2021	474595	1.00	47,400	47,400	00000481	COMPACT CENTRIFUGAL	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
36	LABORATORY CART	135345-49	01/12/2022	474972	2.00	75,000	150,000	00000154	LABORATORY CART	ZAL TECH TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
37	CO2 CYLINDER GAS	135345-49	01/12/2022	474972	2.00	75,000	150,000	00000154	CO2 CYLINDER GAS	ZAL TECH TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
38	Refrigerator 668 Liter	135346	31/12/21	747056/474578	4.00	193,200	772,800	5377	Refrigerator 668 Liter	SOLOMON KEFELE YOHANNES TRADING	IDA/World Bank/ Fund	CDT Africa Laboratory Team
39	DNA THERMAL CYCLER(REAL TIME)	135347	31/12/2021	474900	1.00	1,897,500	1,897,500	00003354	DNA THERMAL CYCLER(REAL TIME)	MORE TECH INDUSTRY PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
40	AN ACTOBIC JAR	135451	31/12/2021	474951	2.00	28,750	57,500	00000133	AN ACTOBIC JAR	RAFINOS LAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
41	GARBEJER TRASH BAG	135451	31/12/2021	474951	4.00	12,420	49,680	00000133	GARBEJER TRASH BAG	RAFINOS LAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
42	DIGITAL COLONY COUNTER	135451	31/12/2021	474951	2.00	19,550	39,100	00000133	DIGITAL COLONY COUNTER	RAFINOS LAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
43	DRYING OVEN 136L	135453	01/12/2022	474973	1.00	98,000	98,000	00001955	DRYING OVEN 136L	WISE TEAM PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
44	HEATING PLATE	135457	01/12/2022	474974	2.00	58,100	116,200	00000492	HEATING PLATE	FIRMAMENT TARDING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
45	MEDIACL EQUIPMENT	136086-785/89	07/07/2022	0941098	1.00	5,094,931	5,094,931	219012037	MEDIACL EQUIPMENT	ANTON PAAR	IDA/World Bank/ Fund	CDT Africa Laboratory Team
46	PURE SOLV MICRO SYSTEM SOLVENT PURIFICATION SYSTEM FULLSET	136087	07/07/2022	0092244	1.00	591,588	591,588	210006	PURE SOLV MICRO SYSTEM SOLVENT PURIFICATION SYSTEM FULLSET	SPOT MEDICAL EQUIPMENT SINTAYEHU & FRIENDS WOOD PARTNERSHIP	IDA/World Bank/ Fund	CDT Africa Laboratory Team
47	KITCHEN CABINET	20436	31/8/21	746789	1.00	36,152	36,152	00000136	KITCHEN CABINET	MS ZG TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
48	Wi-f 4G MOBILE	20446	11/01/2021	746959/474551	1.00	4,000	4,000	00004722	Wi-f 4G MOBILE	EB YES FURNITURE	IDA/World Bank/ Fund	CDT Africa Laboratory Team
49	Guest Chaire	044317	28/02/27	747091/474962	4.00	18,500	74,000	0497	Guest Chaire	EB YES FURNITURE	IDA/World Bank/ Fund	CDT Africa Laboratory Team
50	Swi. Chaire	044317	28/02/27	747091/474962	5.00	7,500	37,500	0497	Swi. Chaire	EB YES FURNITURE	IDA/World Bank/ Fund	CDT Africa Laboratory Team
51	Wi-fi Modem	044305	12/10/2021	747053	1.00	4,000	4,000	00005150	Wi-fi Modem	Ethio Telecom	IDA/World Bank/ Fund	CDT Africa Laboratory Team
52	LABORATORY EQUIPMENT	135440-45	01/08/2022	746326	1.00	1,130,584	1,130,584	2198	LABORATORY EQUIPMENT	Seeding Lab	IDA/World Bank/ Fund	CDT Africa Laboratory Team
53	HEATING MANTLE 250ML	135307	09/09/2021	474599	1.00	5,880	5,880	00000414	HEATING MANTLE 250ML	SCILAB TRADING PLC	IDA/World Bank/ Fund	CDT Africa Laboratory Team
54	WIFI 4G ROUTER	744308	31/12/21	747061/474574	1.00	4,000	4,000	169769355	WIFI 4G ROUTER	Ethio Telecom	IDA/World Bank/ Fund	CDT Africa Laboratory Team
55	HP CORE I7 16GB RAM 1TB HDD	044336	16/6/22	68194	5.00	147,400	737,000	00004305	HP CORE I7 16GB RAM 1TB HDD	MADOT TECHNOLOGY	AHOP PROJECT	Ahop Project Team
56	PULSEOXIMETER FINGER TIP	135338	12/08/2021	474750	8.00	2,600	20,800	00001074	PULSEOXIMETER FINGER TIP	YESHADAM TRADING PLC	ASSET PROJECT	Asset Project Team
57	PULSEOXITMENT FOR PEDIATRIC	135338	12/08/2021	474750	2.00	5,375	10,750	00001074	PULSEOXITMENT FOR PEDIATRIC	YESHADAM TRADING PLC	ASSET PROJECT	Asset Project Team
58	MEETING TABLE	20442	30/9/21	746526	1.00	172,005	172,005	00000344	MEETING TABLE	Solyana Trading & Inv't Plc	ENDPOINT	CDT Africa Laboratory Team
59	EXECUTIVE CHAIRE	20442	30/9/21	746526	1.00	48,695	48,695	00000344	EXECUTIVE CHAIRE	Solyana Trading & Inv't Plc	ENDPOINT	CDT Africa Laboratory Team
60	VISTOR CHAIR	20442	30/9/21	746526	10.00	37,000	370,000	00000344	VISTOR CHAIR	Solyana Trading & Inv't Plc	ENDPOINT	CDT Africa Laboratory Team
61	WIFI 4G ROUTER	044331	23/02/22	747251/49452	1.00	4,280	4,280	169769355	WIFI 4G ROUTER	Ethio Telecom	ENDPOINT-2	Dr. Gernew
62	WIFI 4G ROUTER	044314	30/1/22	746851/474606	1.00	4,280	4,280	169769355	WIFI 4G ROUTER	Ethio Telecom	PTSD PROJECT	Ms. Dagmawit Tesfaye
63	WIFI 4G ROUTER	044337	06/10/2022	746864/	1.00	4,430	4,430	173132216	WIFI 4G ROUTER	Ethio Telecom	PTSD PROJECT	Mr. Moges Dilo
64	MOBILE PHAN/SMART/A22	044337	06/10/2022	746864/	7.00	13,866	97,065	173132216	MOBILE PHAN/SMART/A22	Ethio Telecom	PTSD PROJECT	Ms. Dagmawit Tesfaye
65	VOICE RECORDER	044345	30/6/22	746866/474625	3.00	7,500	22,500	00000131	VOICE RECORDER	YOHANESS ATAKLITE ABREHA	PTSD PROJECT	Ms. Dagmawit Tesfaye
66	WIFI 4G ROUTER	044331	04/01/2022	746714/69269	2.00	4,280	8,560	169769355	WIFI 4G ROUTER	Ethio Telecom	UHEP PROJECT	Ms. Eyerusalem Getachew
67	SERVER	044325	19/4/22	68995	1.00	844,517	844,517	00000118	SERVER	INTELLIGINT TECH.	CLINOPS PROJECT	Mr. Wondwosen Tensu

ADDIS ABABA UNIVERSITY-CDT AFRICA
FIXED ASSET REGISTER FORM-CONSOLIDATED
FOR THE PERIOD END OF JULY 07, 2022

No	Name of Fixed Asset	GRN Number	Acquisition Date	Procured pV/JV No	Quantity (pcs)	Unit Price with VAT	Total Price with VAT	Receipt Number	Type of the Asset	Supplier Name	Project Fund/Grant/	Location/ FA Holder
68	EXTERNAL HARD DISK	044339	20/6/22	816856	2.00	7,900	15,800	3708	EXTERNAL HARD DISK	TSEGA RETA IMPORTER	CLINOPS PROJECT	Clinops Project Team
69	KYOCERA M5521CDW	044340	22/6/22	746663	3.00	36,500	109,500	00004016	KYOCERA M5521CDW	NATIONAL MARKETER PLC	CLINOPS PROJECT	Clinops Project Team
70	TYPE C TO HDML	20434	31/8/21	746658	3.00	4,500	13,500	00002129	TYPE C TO HDML	MADOT TECHNOLOGY	CLINOPS PROJECT	Clinops Project Team
71	WIFI 4G ROUTER	20436	31/8/21	746656	1.00	4,030	4,030	00001940	WIFI 4G ROUTER	Ethio Telecom	CLINOPS PROJECT	Clinops Project Team
72	ROUTER	20439	30/9/21	746659	5.00	4,001	20,000	00003742	ROUTER	MS ZG TRADING PLC	CLINOPS PROJECT	Dr. Dawit Asmanaw
73	Conference room equipment	20447	11/05/2021	68979	1.00	2,849,780	2,849,780	00000828	Conference room equipment	IRACK IT SOLUTION	CLINOPS PROJECT	Clinops Project Team
74	SMART BOARD	044309	17/1/22	68986	1.00	873,678	873,678	00000095	SMART BOARD	ALTA COMPUTER PLC	CLINOPS PROJECT	Clinops Project Team
75	I7 OPS PC	044309	17/1/22	68986	1.00	183,917	183,917	00000095	I7 OPS PC	ALTA COMPUTER PLC	CLINOPS PROJECT	Mr. Wondwosen Tensu
76	TV MOUNT	044309	17/1/22	68986	1.00	285,828	285,828	00000095	TV MOUNT	ALTA COMPUTER PLC	CLINOPS PROJECT	Mr. Wondwosen Tensu
77	Gaming Desktop Comp. and Monitor 27"	044346/47	30/6/22	746664	1.00	1,280,345	1,280,345	00000118	Gaming Desktop Comp. and Monitor 27"	ALTA COMPUTER PLC	CLINOPS PROJECT	Mr. Wondwosen Tensu
										Interlize Techno Heyle	CLINOPS PROJECT	Clinops Project Team
							28,173,729					

